(4-甲氧基苄基)-(3-吗啉-4-丙基)胺 | 436096-93-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-甲氧基苄基)-(3-吗啉-4-丙基)胺
• 英文名称: (4-Methoxy-benzyl)-(3-morpholin-4-yl-propyl)-amine
• 英文别名: N-[(4-methoxyphenyl)methyl]-3-morpholin-4-ylpropan-1-amine
• CAS: 436096-93-4
• 化学式: C₁₅H₂₄N₂O₂
• mdl: MFCD01475412
• 分子量: 264.368
• InChiKey: SLWQNNULQQDKPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  33.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  (2SR,3RS)-3-(4-chlorophenyl)-5-oxo-4-(4-(pyridin-4-ylmethyl)phenyl)morpholine-2-carboxylic acid 、 (4-甲氧基苄基)-(3-吗啉-4-丙基)胺 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.17h， 以46%的产率得到(2SR,3RS)-3-(4-chlorophenyl)-N-(4-methoxybenzyl)-N-(3-morpholinopropyl)-5-oxo-4-(4-(pyridin-4-ylmethyl)phenyl)morpholine-2-carboxamide
  参考文献：
  名称：

  Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction

  摘要：

  Five lactam chemotypes amenable by the Castagnoli-Cushman reaction of imines and cyclic anhydrides have been investigated for their ability to activate p53 tumor suppressing transcription factor thus induce apoptosis in p53(+) cancer cells. A virtual library of 1.07 million chemically diverse compounds based on these scaffolds was subjected to in silico screening first. The compounds displaying high docking score were visually prioritized to identify the best-fitting compounds, i.e. the ones which adequately mimic the interactions of clinical candidate inhibitor Nutlin-3a. These 38 compounds were synthesized and tested for apoptosis induction in p53(+) H116 cancer cells to identify 9 potent apoptosis-inducers (two of them exceeding the activity of Nutlin-3a) which belonged to four different chemotypes. The activation of p53 involved in the proapoptotic activity observed was supported by effective induction of EGFP expression in human osteocarcinoma U2OS-pLV reporter cell line. Moreover, the two most potent apoptosis inducers displayed antiproliferative profile identical to several known advanced p53 activators: they inhibited the growth of p53(+/+) HCT116 cells in much lower concentration range compared to p53(+/+) HCT116 cells. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2018.04.036

文献信息

• Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction
  作者：Mikhail Krasavin、Maxim A. Gureyev、Dmitry Dar'in、Olga Bakulina、Maria Chizhova、Anastasia Lepikhina、Daria Novikova、Tatyana Grigoreva、Gleb Ivanov、Aisulu Zhumagalieva、Alexander V. Garabadzhiu、Vyacheslav G. Tribulovich

  DOI：10.1016/j.bmc.2018.04.036

  日期：2018.5

  Five lactam chemotypes amenable by the Castagnoli-Cushman reaction of imines and cyclic anhydrides have been investigated for their ability to activate p53 tumor suppressing transcription factor thus induce apoptosis in p53(+) cancer cells. A virtual library of 1.07 million chemically diverse compounds based on these scaffolds was subjected to in silico screening first. The compounds displaying high docking score were visually prioritized to identify the best-fitting compounds, i.e. the ones which adequately mimic the interactions of clinical candidate inhibitor Nutlin-3a. These 38 compounds were synthesized and tested for apoptosis induction in p53(+) H116 cancer cells to identify 9 potent apoptosis-inducers (two of them exceeding the activity of Nutlin-3a) which belonged to four different chemotypes. The activation of p53 involved in the proapoptotic activity observed was supported by effective induction of EGFP expression in human osteocarcinoma U2OS-pLV reporter cell line. Moreover, the two most potent apoptosis inducers displayed antiproliferative profile identical to several known advanced p53 activators: they inhibited the growth of p53(+/+) HCT116 cells in much lower concentration range compared to p53(+/+) HCT116 cells. (C) 2018 Elsevier Ltd. All rights reserved.